The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to plixorafenib as a potential treatment for adults with high-grade gliomas carrying…
Glioma
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Telix Pharmaceuticals seeking approval of TLX101-Px, the company’s experimental imaging…
The U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to the experimental radiation therapy rhenium Re186 obisbemeda — slated to be marketed…
GLIX1, a treatment for recurrent and progressive glioblastoma and other high-grade gliomas, has begun human testing in a Phase 1/2a clinical trial, said…
Myosin Therapeutics has been awarded $2 million in funding to support a Phase 1/2 clinical trial testing its lead experimental cancer therapy, MT-125, in…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMXT 1501 to treat malignant…
Inovio Pharmaceuticals and Akeso have entered into a clinical trial collaboration and supply agreement to evaluate a novel immunotherapy combining INO-5412 plus cadonilimab…
A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of pediatric low-grade glioma (pLGG).
An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food and Drug Administration (FDA). The…
Telix Pharmaceuticals has submitted an application to European regulators seeking approval for TLX101-Px, the company’s experimental imaging agent designed to help guide treatment decisions…
